163 related articles for article (PubMed ID: 25897240)
1. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit.
Maggiore C; Vazquez JA; Guervil DJ; Ramani A; Jandourek A; Cole P; Friedland HD
Ther Clin Risk Manag; 2015; 11():557-63. PubMed ID: 25897240
[TBL] [Abstract][Full Text] [Related]
2. Ceftaroline Fosamil for the Treatment of
Vazquez JA; Maggiore CR; Cole P; Smith A; Jandourek A; Friedland HD
Infect Dis Clin Pract (Baltim Md); 2015 Jan; 23(1):39-43. PubMed ID: 25574117
[TBL] [Abstract][Full Text] [Related]
3. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
Udeani G; Evans J; Cole P; Friedland HD
Hosp Pract (1995); 2014 Aug; 42(3):109-15. PubMed ID: 25255412
[TBL] [Abstract][Full Text] [Related]
4. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
Guervil DJ; Kaye KS; Hassoun A; Cole P; Huang XY; Friedland HD
J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
[TBL] [Abstract][Full Text] [Related]
5. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Maggiore C; Pasquale T; Cole P; Friedland HD
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
[TBL] [Abstract][Full Text] [Related]
6. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience.
Ramani A; Udeani G; Evans J; Jandourek A; Cole P; Smith A; David Friedland H
J Chemother; 2014 Aug; 26(4):229-34. PubMed ID: 24650326
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.
Evans JD; Udeani G; Cole P; Friedland HD
Postgrad Med; 2014 Sep; 126(5):128-34. PubMed ID: 25295657
[TBL] [Abstract][Full Text] [Related]
8. Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE.
Carreno JJ; Lodise TP
Infect Dis Ther; 2014 Dec; 3(2):123-32. PubMed ID: 25193094
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
Kaye KS; Udeani G; Cole P; Friedland HD
Hosp Pract (1995); 2015; 43(3):144-9. PubMed ID: 25956849
[TBL] [Abstract][Full Text] [Related]
10. Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam.
Sánchez-García M; Hammond J; Yan JL; Kantecki M; Ansari W; Dryden M
Infect Dis Ther; 2020 Sep; 9(3):609-623. PubMed ID: 32607967
[TBL] [Abstract][Full Text] [Related]
11. Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience.
Johnson LB; Ramani A; Guervil DJ
BMC Infect Dis; 2019 Feb; 19(1):183. PubMed ID: 30791894
[TBL] [Abstract][Full Text] [Related]
12. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.
Welte T; Kantecki M; Stone GG; Hammond J
Int J Antimicrob Agents; 2019 Oct; 54(4):410-422. PubMed ID: 31404620
[TBL] [Abstract][Full Text] [Related]
13. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
File TM; Wilcox MH; Stein GE
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
[TBL] [Abstract][Full Text] [Related]
15. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
16. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
17. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.
Lipsky BA; Cannon CM; Ramani A; Jandourek A; Calmaggi A; Friedland HD; Goldstein EJ
Diabetes Metab Res Rev; 2015 May; 31(4):395-401. PubMed ID: 25417910
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]